03:27 AM EDT, 10/11/2026 (MT Newswires) -- Middle East Pharmaceutical Industries Co. (SASE:4016), d/b/a Avalon Pharma, secured an exclusive license from India-based OneSource Specialty Pharma to register and market Tirzepatide multi-dose pen in Saudi Arabia and other markets in the Middle East and North Africa region. The Tadawul-listed pharmaceutical company may also request the transfer of the manufacturing technology following the product's commercialization, according to a Sunday release. The 10-year contract, with automatic one-year renewals, is poised to deliver cumulative revenue of at least 800 million Saudi riyals in the first five years.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.